论文部分内容阅读
GlaxoSmithKline公司的抗病毒药物伐昔洛韦（valaciclovir，Valtrex）获美国FDA的增补新药申请，用于短程治疗复发的生殖器疱疹。新标签将允许病人以一日2次（而非5次），每次1粒500mg胶囊治疗复发的生殖器疱疹。本品获得许可用于起始和复发时治疗和抑制生殖器疱疹。美国有5000
GlaxoSmithKline’s antiviral drug valaciclovir (Valtrex) was approved by the U.S. FDA as a new drug for short-term treatment of recurrent genital herpes. The new label will allow patients to treat recurrent genital herpes one capsule 500mg at a time instead of five times a day. This product is licensed for the treatment and suppression of genital herpes on initiation and relapse. The United States has 5000